TY - JOUR AU - Gauthier, Marc AU - Chakraborty, Krishnendu AU - Oriss, Timothy B. AU - Raundhal, Mahesh AU - Das, Sudipta AU - Chen, Jie AU - Huff, Rachael AU - Sinha, Ayan AU - Fajt, Merritt AU - Ray, Prabir AU - Wenzel, Sally E. AU - Ray, Anuradha T1 - Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias PY - 2017/07/06/ AB - We previously showed that Th1/type 1 inflammation marked by increased IFN-γ levels in the airways can be appreciated in 50% of patients with severe asthma, despite high dose corticosteroid (CS) treatment. We hypothesized that a downstream target of IFN-γ, CXCL10, which recruits Th1 cells via the cognate receptor CXCR3, is an important contributor to Th1high asthma and CS unresponsiveness. We show high levels of CXCL10 mRNA closely associated with IFNG levels in the BAL cells of 50% of severe asthmatics and also in the airways of mice subjected to a severe asthma model, both in the context of high-dose CS treatment. The inability of CS to dampen IFNG or CXCL10 expression was not because of impaired nuclear translocation of the glucocorticoid receptor (GR) or its transactivational functions. Rather, in the presence of CS and IFN-γ, STAT1 and GR were recruited on critical regulatory elements in the endogenous CXCL10 promoter in monocytes, albeit without any abatement of CXCL10 gene expression. High CXCL10 gene expression was also associated with a mast cell signature in both humans and mice, CXCR3 being also expressed by mast cells. These findings suggest that the IFN-γ–CXCL10 axis plays a central role in persistent type 1 inflammation that may be facilitated by CS therapy through GR-STAT1 cooperation converging on the CXCL10 promoter. JF - JCI Insight JA - JCI Insight SN - 2379-3708 DO - 10.1172/jci.insight.94580 VL - 2 IS - 13 UR - https://doi.org/10.1172/jci.insight.94580 PB - The American Society for Clinical Investigation ER -